HRP20120684T1 - Imunglobulini protiv nogo - Google Patents

Imunglobulini protiv nogo Download PDF

Info

Publication number
HRP20120684T1
HRP20120684T1 HRP20120684TT HRP20120684T HRP20120684T1 HR P20120684 T1 HRP20120684 T1 HR P20120684T1 HR P20120684T T HRP20120684T T HR P20120684TT HR P20120684 T HRP20120684 T HR P20120684T HR P20120684 T1 HRP20120684 T1 HR P20120684T1
Authority
HR
Croatia
Prior art keywords
seq
amino acid
acid sequence
antibody
host cell
Prior art date
Application number
HRP20120684TT
Other languages
English (en)
Croatian (hr)
Inventor
Jane Clegg Stephanie
Henry Ellis Jonathan
Germaschewski Volker
Andrew Hamblin Paul
Kopsidas George
Mcadam Ruth
Kumar Prinjha Rabinder
Original Assignee
Glaxo Group Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35736284&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20120684(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxo Group Limited filed Critical Glaxo Group Limited
Publication of HRP20120684T1 publication Critical patent/HRP20120684T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
    • C07K16/465—Igs containing CDR-residues from one specie grafted between FR-residues from another with additional modified FR-residues
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Mycology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HRP20120684TT 2005-12-16 2006-12-14 Imunglobulini protiv nogo HRP20120684T1 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0525662.3A GB0525662D0 (en) 2005-12-16 2005-12-16 Immunoglobulins
PCT/EP2006/069737 WO2007068750A2 (en) 2005-12-16 2006-12-14 Immunoglobulins directed against nogo

Publications (1)

Publication Number Publication Date
HRP20120684T1 true HRP20120684T1 (hr) 2012-09-30

Family

ID=35736284

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20120684TT HRP20120684T1 (hr) 2005-12-16 2006-12-14 Imunglobulini protiv nogo

Country Status (30)

Country Link
US (2) US8362208B2 (https=)
EP (2) EP2228391A3 (https=)
JP (1) JP5015949B2 (https=)
KR (1) KR101355118B1 (https=)
CN (1) CN101374863B (https=)
AR (1) AR057239A1 (https=)
AU (1) AU2006325228B2 (https=)
BR (1) BRPI0619855A2 (https=)
CA (1) CA2633501C (https=)
CR (1) CR10099A (https=)
CY (1) CY1113094T1 (https=)
DK (1) DK1960429T3 (https=)
EA (1) EA015536B1 (https=)
ES (1) ES2389380T3 (https=)
GB (1) GB0525662D0 (https=)
HR (1) HRP20120684T1 (https=)
IL (1) IL192086A0 (https=)
JO (1) JO2795B1 (https=)
MA (1) MA30041B1 (https=)
MY (1) MY149492A (https=)
NO (1) NO20082699L (https=)
NZ (1) NZ569143A (https=)
PE (1) PE20071099A1 (https=)
PL (1) PL1960429T3 (https=)
PT (1) PT1960429E (https=)
SI (1) SI1960429T1 (https=)
TW (1) TWI378940B (https=)
UA (1) UA96279C2 (https=)
WO (1) WO2007068750A2 (https=)
ZA (2) ZA200805111B (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2009258063B2 (en) 2007-06-21 2014-09-25 Macrogenics, Inc. BCR-complex-specific antibodies and methods of using same
HRP20130699T1 (hr) * 2007-11-02 2013-11-22 Novartis Ag Poboljšane molekule koje se vežu na nogo-a i njihova farmaceutska uporaba
PE20091829A1 (es) 2008-05-06 2009-12-12 Glaxo Group Ltd Encapsulacion de agentes biologicamente activos
JP2011527317A (ja) * 2008-07-11 2011-10-27 グラクソ グループ リミテッド Ｎｏｇｏ−ａアンタゴニストによる筋萎縮性側索硬化症の治療
WO2012004773A1 (en) 2010-07-09 2012-01-12 Universite De Geneve New uses of nogo-a inhibitors and related methods
KR20150036398A (ko) 2012-07-05 2015-04-07 글락소 그룹 리미티드 근육위축가쪽경화증의 치료에서의 항­ｎｏｇｏ­ａ 항체의 최적 투여 섭생
US20180362660A1 (en) * 2016-05-09 2018-12-20 Schickwann Tsai Anti-penumbra monoclonal antibodies for detection and therapy of normal and abnormal B lymphocytes
WO2018232144A1 (en) * 2017-06-14 2018-12-20 Monojul, Llc High-affinity anti-human folate receptor beta antibodies and methods of use
WO2020250204A1 (ko) * 2019-06-13 2020-12-17 프레스티지 바이오파마 피티이. 엘티디. 신규 cthrc1에 특이적 항체 및 이의 용도
WO2021079002A2 (en) 2019-10-24 2021-04-29 Novago Therapeutics Ag Novel anti-nogo-a antibodies
GB202012331D0 (en) 2020-08-07 2020-09-23 Petmedix Ltd Therapeutic antibodies
EP4355782A1 (en) 2021-06-17 2024-04-24 Petmedix Ltd. Anti canine cd20 antibodies
MX2024004875A (es) 2021-10-21 2024-07-19 Petmedix Ltd Proteinas que comprenden en el dominio extracelular de p75ntr.
CN116251181B (zh) * 2021-12-02 2023-09-22 北京东方百泰生物科技股份有限公司 一种抗tslp单克隆抗体的注射制剂
US20250340659A1 (en) 2022-02-09 2025-11-06 PetMedix Ltd. Therapeutic antibodies
CN119768424A (zh) * 2022-08-22 2025-04-04 舒泰神（北京）生物制药股份有限公司 特异性识别Nogo-A的抗体及其应用
GB202217993D0 (en) 2022-11-30 2023-01-11 Petmedix Ltd Therapeutic antibodies
AU2024217925A1 (en) 2023-02-09 2025-08-14 Zoetis Services Uk Limited Therapeutic molecules comprising variants of the extracellular domain of p75 neurotrophin receptor (p75ntr)
WO2026041734A1 (en) 2024-08-22 2026-02-26 Novago Therapeutics Ag Methods for treating neurological disorders using anti-nogo-a antibodies

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57106673A (en) 1980-12-24 1982-07-02 Chugai Pharmaceut Co Ltd Dibenzo(b,f)(1,4)oxazepin derivative
DD266710A3 (de) 1983-06-06 1989-04-12 Ve Forschungszentrum Biotechnologie Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
WO1988007089A1 (en) 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
US4873316A (en) 1987-06-23 1989-10-10 Biogen, Inc. Isolation of exogenous recombinant proteins from the milk of transgenic mammals
US5250414A (en) 1988-11-04 1993-10-05 Erziehungsdirektion Of The Canton Zurich Diagnostic methods using neurite growth regulatory factors
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
EP0656064B1 (en) 1992-08-17 1997-03-05 Genentech, Inc. Bispecific immunoadhesins
GB9403250D0 (en) 1994-02-21 1994-04-13 Univ Mcgill Therapeutic use of myelin-associated glycoprotein (mag)
US5429746A (en) 1994-02-22 1995-07-04 Smith Kline Beecham Corporation Antibody purification
DK0804419T3 (da) 1994-05-27 2003-11-24 Glaxosmithkline Spa Quinolinderivater som tachykinin NK 3-receptor-antagonister
GB9424449D0 (en) 1994-12-02 1995-01-18 Wellcome Found Antibodies
ATE275415T1 (de) 1995-06-27 2004-09-15 Res Foundation Of Cuny Hunter Zusamenzetzung enthaltend einen inhibitor des myelin assoziierten glycoproteins (mag), welcher einer veränderten oder mutierten form von mag enthält
US6420338B1 (en) * 1997-06-13 2002-07-16 New York University Medical Center Inhibition of the Src kinase family pathway as a method of treating HBV infection and hepatocellular carcinoma
GB9809839D0 (en) 1998-05-09 1998-07-08 Glaxo Group Ltd Antibody
DE69942803D1 (de) 1998-07-22 2010-11-11 Smithkline Beecham Ltd Rotein änhelt, und dafür kodierende cdns
CZ304224B6 (cs) 1998-11-06 2014-01-15 Schwab Monoklonální protilátka
FR2792199B3 (fr) 1999-04-13 2001-05-18 Sanofi Sa Utilisation de l'osanetant pour la preparation de medicaments utiles dans le traitement des troubles de l'humeur
MXPA05000511A (es) 2001-07-12 2005-09-30 Jefferson Foote Anticuepros super humanizados.
GB0228832D0 (en) 2002-12-10 2003-01-15 Novartis Ag Organic compound
GB0318727D0 (en) 2003-08-08 2003-09-10 Smithkline Beecham Corp Novel compounds
DE10338136A1 (de) 2003-08-15 2005-03-24 European Molecular Biology Laboratory Zentrifuge und ein Träger zur Verwendung in einer Zentrifuge
GB0321997D0 (en) 2003-09-19 2003-10-22 Novartis Ag Organic compound
CA2549956C (en) * 2003-12-22 2016-04-12 Glaxo Group Limited Immunoglobulins
JP4782700B2 (ja) * 2004-01-20 2011-09-28 カロバイオス ファーマシューティカルズ インコーポレイティッド 最低限必須な結合決定基を用いた抗体特異性の移入
US7973139B2 (en) * 2004-03-26 2011-07-05 Human Genome Sciences, Inc. Antibodies against nogo receptor

Also Published As

Publication number Publication date
TW200801038A (en) 2008-01-01
CR10099A (es) 2008-09-22
US20130287781A1 (en) 2013-10-31
ES2389380T3 (es) 2012-10-25
TWI378940B (en) 2012-12-11
JP5015949B2 (ja) 2012-09-05
CN101374863A (zh) 2009-02-25
CA2633501C (en) 2015-03-31
EP1960429A2 (en) 2008-08-27
GB0525662D0 (en) 2006-01-25
KR20080080644A (ko) 2008-09-04
PE20071099A1 (es) 2007-11-22
JO2795B1 (en) 2014-03-15
UA96279C2 (ru) 2011-10-25
ZA200805111B (en) 2009-12-30
EP2228391A2 (en) 2010-09-15
PL1960429T3 (pl) 2012-11-30
CY1113094T1 (el) 2016-04-13
EP2228391A3 (en) 2010-12-29
AU2006325228A1 (en) 2007-06-21
AR057239A1 (es) 2007-11-21
PT1960429E (pt) 2012-09-25
BRPI0619855A2 (pt) 2011-10-25
US8362208B2 (en) 2013-01-29
CA2633501A1 (en) 2007-06-21
US20100221260A1 (en) 2010-09-02
ZA200906162B (en) 2010-05-26
IL192086A0 (en) 2008-12-29
CN101374863B (zh) 2013-05-29
MY149492A (en) 2013-09-13
KR101355118B1 (ko) 2014-02-06
JP2009519025A (ja) 2009-05-14
EA015536B1 (ru) 2011-08-30
WO2007068750A2 (en) 2007-06-21
EA200801343A1 (ru) 2008-12-30
EP1960429B1 (en) 2012-06-27
HK1119720A1 (en) 2009-03-13
NO20082699L (no) 2008-09-08
SI1960429T1 (sl) 2012-09-28
AU2006325228B2 (en) 2011-12-15
DK1960429T3 (da) 2012-09-24
MA30041B1 (fr) 2008-12-01
WO2007068750A3 (en) 2007-11-29
NZ569143A (en) 2011-08-26

Similar Documents

Publication Publication Date Title
HRP20120684T1 (hr) Imunglobulini protiv nogo
RU2613422C2 (ru) Антитело к blys
Hu et al. [Retracted] Side‐by‐Side Comparison of the Biological Characteristics of Human Umbilical Cord and Adipose Tissue‐Derived Mesenchymal Stem Cells
ME02341B (me) Nova antitijela za inhibiciju c-met dimerizacije i njihova upotreba
ES2556630T3 (es) Medio condicionado para células progenitoras de hígado
JP5828916B2 (ja) 幹細胞のインビボ移動誘導方法
TWI629284B (zh) 多價抗體片段與其三聚複合物
FI3250592T3 (fi) Transtyretiinin vastaisia vasta-aineita
RU2012143793A (ru) Биспецифические двухвалентные антитела анти-vegf/анти-ang-2
WO2022166802A1 (zh) 抗人cd271的单克隆抗体及用途
RU2009118621A (ru) Агонистические антитела против notch3 и их применение для лечения ntch3-ассоциированных заболеваний
JP2010162028A (ja) 選択的ｎｇｆ経路インヒビターとしてのヒト抗ｎｇｆ中和抗体
CN106046166A (zh) 结合人蛋白酪氨酸磷酸酶β(HPTPβ)的抗体及其用途
CN103936854A (zh) 抗il-17a单克隆抗体及其制备与应用
Tian et al. Fecal microbiota transplantation enhances cell therapy in a rat model of hypoganglionosis by SCFA‐induced MEK1/2 signaling pathway
JP2020073503A (ja) タンパク質産生方法
Gandhi et al. Stellate cells in health and disease
RU2017134042A (ru) ДИМЕРЫ SCFV-FC, КОТОРЫЕ СВЯЗЫВАЮТСЯ С ТРАНСФОРМИРУЮЩИМ ФАКТОРОМ РОСТА β1 С ВЫСОКОЙ АФФИННОСТЬЮ, АВИДНОСТЬЮ И СПЕЦИФИЧНОСТЬЮ
Mehta et al. Amelioration of collagen antibody induced arthritis in mice by an antibody directed against the fibronectin type III repeats of tenascin-C: Targeting fibronectin type III repeats of tenascin-C in rheumatoid arthritis
CN101245106B (zh) 抗vegf受体单克隆抗体及其制备方法和应用
CN109517064A (zh) 白介素-6的人源化单克隆抗体、其编码基因及应用
CN114591432B (zh) 抗TNFα的单域抗体及其用途
CN118001428B (zh) 基因修饰干细胞在il-17靶点相关疾病中的应用
WO2020156220A1 (zh) 人源化抗Aβ单克隆抗体及其应用
JP2022513224A (ja) 抗ｉｌ‐１７ａ抗体及びその適用